Hypertension and Afro-descendant ethnicity: A bad interaction for lupus nephritis treated with cyclophosphamide?

Lupus

Volumn 16, Issue 9, 2007, Pages 724-730

  De Castro, Waldir Pedro ^a,b,d,e   Morales, J V ^a,c   Wagner, M B ^a   Graudenz, M ^b   Edelweiss, M I ^c   Goncalves L F ^a,c  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b UNIVERSIDADE FEDERAL DE CIÊNCIAS DA SAÚDE DE PORTO ALEGRE   (Brazil)

^c HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^d Nephrology Division   (Brazil)

^e NONE   (Brazil)

Author keywords

Cyclophosphamide; Ethnicity; Hypertension; Lupus nephritis; Prognosis

Indexed keywords

AZATHIOPRINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CREATININE; CYCLOPHOSPHAMIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; PREDNISONE;

ADULT; AFRICA; ANEMIA; ARTICLE; CAUCASIAN; COHORT ANALYSIS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG MEGADOSE; ETHNIC DIFFERENCE; ETHNICITY; FEMALE; HEMODIALYSIS; HUMAN; HUMAN TISSUE; HYPERTENSION; KIDNEY BIOPSY; KIDNEY FUNCTION; LUPUS ERYTHEMATOSUS NEPHRITIS; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MULTIPLE LINEAR REGRESSION ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROTEINURIA; RETROSPECTIVE STUDY; SAMPLE; STATISTICAL SIGNIFICANCE; SURVIVAL; TREATMENT RESPONSE;

ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; ANEMIA; BRAZIL; COHORT STUDIES; CREATININE; CYCLOPHOSPHAMIDE; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; HYPERTENSION; IMMUNOSUPPRESSIVE AGENTS; LINEAR MODELS; LUPUS NEPHRITIS; MALE; MIDDLE AGED; PROGNOSIS; PROTEINURIA; RENAL DIALYSIS; RETROSPECTIVE STUDIES;

EID: 34948907222     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1177/0961203307081114     Document Type: Article

References (36)

1. Bono L, Cameron JS, Hicks JA. The very long-term prognosis and complications of lupus nephritis and its treatment. Q J Med 1999; 92: 211-221.
2. Balow JE, Austin HA III, Muenz LR et al. Effect of treatment on the evolution of renal abnormalities in lupus nephritis. New Engl J Med 1984; 311: 491-495.
3. Austin HA III, Klippel JH, Balow JE et al. Therapy of lupus nephritis: controlled trial of prednisone and cytotoxic drugs. New Engl J Med 1986; 314: 614-619.
4. Steinberg AD, Steinberg SC. Long-term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisolone alone. Arthritis Rheum 1991; 34: 945-950.
5. Flanc RS, Roberts MA, Strippoli GFM, Chadban SJ, Kerr PG, Atkins RC. Treatment for lupus nephritis [Systematic Review], Cochrane Renal Group. The Cochrane Database of Systematic Reviews 2004, Issue 1, Art. No.: CD002922, DOI: 10.1002/14651858. CD002922.pub2.
6. Contreras G, Pardo V, Leclercq B et al. Sequential therapies for proliferative lupus nephritis. New Engl J Med 2004; 350: 971-980.
7. Houssiau FA, Vasconcelos C, D'Cruz D et al. Immunosuppressive therapy in lupus nephritis: the Euro-lupus nephritis trial, a randomised trial of low-dose versus high-dose cyclophosphamide. Arthritis Rheum 2002; 46: 2121-2131.
8. Kuiper-Geertsma DG, Derksen RHWM. Newer drugs for the treatment of lupus nephritis. Drugs 2003; 63(2): 167-180.
9. Houssiau FA. Management of lupus nephritis: an update. J Am Soc Nephrol 2004; 15: 2694-2704.
10. Sfikakis PP, Boletis JN, Tsokos GC. Rituximab anti-B-cell therapy in systemic lupus erythematosus: pointing to the future. Curr Opin Rheumatol 2005; 17: 550-557.
11. Dooley MA, Cosio FG, Nachman PH et al. Mycophenolate mofetil therapy in lupus nephritis: clinical observations. J Am Soc Nephrol 1999; 10: 833-839.
12. Chan TM, Li FK, Tang CSO et al. for the Hong Kong-Juangzhou Nephrology Study Group. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. New Engl J Med 2000; 343: 1156-1162.
13. Chan TM, Tse KC, Tang CSO et al. for the Hong Kong-Juangzhou Nephrology Study Group. Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. J Am Soc Nephrol 2005; 16: 1076-1084.
14. Ginzler EM, Dooley MA, Aranow C et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. New Engl J Med 2005; 353: 2219-2228.
15. Dooley MA, Hojan S, Jennette C, Falk R for the glomerular disease collaborative network. Cyclophosphamide therapy for lupus nephritis: poor renal survival in black Americans. Kidney Int 1997; 51: 1188-1196.
16. Austin HA III, Boumpas DT, Vaughn EM et al. High risk features of lupus nephritis: importance of race and clinical and histological factors in 166 patients. Nephrol Dial Transplant 1995; 10: 1620-1628.
17. Austin HA III, Boumpas DT, Vaughn EM et al. Predicting renal outcomes in severe lupus nephritis: contributions of clinical and histological data. Kidney Int 1994; 45: 544-550.
18. Barr RG, Seliger S, Appel GB et al. Prognosis in proliferative lupus nephritis: the role of social-economic status an race/ethnicity. Nephrol Dial Transplant 2003; 18: 2039-2046.
19. Roman MJ, Shanker BA, Davis A et al. Variables associated with decreased survival in systemic lupus erythematosus. Semin Arthitis Rheum 1991; 21: 73-80.
20. Neumann K, Wallace DJ, Azen C et al. Lupus in the 1980s: III. Influence of clinical variables, biopsy and treatment on the outcome in 150 patients with lupus nephritis seen at a single center. Semin Arthritis Rheum 1995; 25: 47-55.
21. Lilleby V, Flato B, Forre O. Disease duration, hypertension and medication requirements are associated with organ damage in childhood-onset systemic lupus erythematosus. Clin Exp Rheumatol 2005; 23: 261-269.
22. Mok CC. Prognostic factors in lupus nephritis. Lupus 2005; 14: 39-44.
23. Austin HA III, Muenz LR, Goyee KM et al. Diffuse proliferative lupus nephritis: Identification of specific pathologic features affecting renal outcome. Kidney Int 1984; 25: 689-695.
24. Najafi CC, Korbet SM, Lewis EJ et al. for de Collaborative Study Group. Significance of histologic patterns of glomerular injury upon long-term prognosis in severe lupus glomerulonephritis. Kidney Int 2001; 59: 2156-2163.
25. Cortés-Hernández J, Ordi-Ros J, Lubnador M et al. Predictors of poor renal outcome in patients with lupus nephritis treated with combined pulses of cyclophosphamide and methylprednisolone. Lupus 2003; 12: 287-296.
26. Ginzler EM, Felson DT, Anthony JM et al. Hypertension increases the risk of renal deterioration in systemic lupus erythematosus. J Rheumatol 1993; 20: 1694-1700.
27. Lea JP. Lupus nephritis in African-Americans. Am J Med Sci 2002; 323: 85-89.
28. Korbert SM, Lewis EJ, Schwartz MM et al. for the Lupus Nephritis Collaborative Study Group. Factors predictive of outcome in severe lupus nephritis. Am J Kidney Dis 2000; 35: 904-914.
29. Mok CC, Ying KY, Tang S et al. Predictors and outcome of renal flares after successful cyclophosphamide treatment for diffuse proliferative lupus glomerulonephritis. Arthritis Rheum 2004; 50: 2559-2568.
30. Chan TM. Preventing renal failure in patients with severe lupus nephritis. Kidney Int 2005; 67: 5116-5119.
31. Arce-Salinas CA, Villa AR, Martinez-Rueda JO et al. Factors associated with chronic renal failure in 121 patients with diffuse proliferative lupus nephritis: a case-control study. Lupus 1995; 4: 197-203.
32. Contreras G, Lenz O, Pardo V et al. Outcomes in African Americans and Hispanics with lupus nephritis. Kidney Int 2006; 69: 1846-1851.
33. Churg J, Bernstein J, Glassock RJ. Renal disease: classification and atlas of glomerular diseases, 2nd edition. New York, Tokyo: Igaku-Shoin, 1995.
34. Altman DJ. Practical statistics for medical research. London: Chapman & Hall/CRC, 1991: 396-439.
35. Hariharan S, McBride MA, Cherikh WS et al. Post-transplant renal function in the first year predicts long-term kidney transplant survival. Kidney Int 2002; 62: 311-318.
36. Rodriguez-Iturbe B, Johnson RJ. Role of inflammatory cells in the kidney in the induction and maintenance of hypertension. Nephrol Dial Transplant 2006; 21: 260-263.